Sorrento Therapeutics, Inc.(SRNE)

Description: Sorrento Therapeutics, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel and proprietary biotherapeutics for the treatment of cancer, inflammation, metabolic, and infectious diseases in the United States. The company's G-MAB, a human antibody library platform, facilitates the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. Its human antibody library technology is used to construct large human antibody libraries. It has license agreement with OPKO Health, Inc. to develop, manufacture, use, market, sell, offer to sell, import, and export certain products related to the development, manufacture, marketing, and sale of drugs for ophthalmological indications. Sorrento Therapeutics, Inc. is based in San Diego, California.

---

Keywords: Medicine Biotechnology Cancer Biopharmaceutical Biology Disease Infectious Diseases Immunology Immune System Treatment Of Cancer Inflammation Antibody Monoclonal Antibody Therapeutic Products Opko Health Antibody Therapy

---

Home Page: www.sorrentotherapeutics.com

SRNE Technical Analysis

4955 Directors Place
San Diego, CA 92121
United States
Phone: 858 203 4100

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)